Pioneering platform to generate novel therapies with potential to treat a wide range of diseases Financing led by Science Creates Ventures and Meltwind to fund development of the platform and initial product candidates BRISTOL, UK, 23 May 2023 – Scarlet Therapeutics (“Scarlet”), a leader in red blood cell-based therapeutics, announces today that it has raised […]
In episode four of Optimum Perspectives Podcast, our in-house IR expert, ex-Fund Manager Eva Haas interviewed Dan Mahony, Chairman of the BioIndustry Association (BIA), following his appointment as UK Life Sciences Investment Envoy to hear his plans for championing the UK’s Life Sciences industry. Dan’s circuitous and unplanned journey to his current role involved among […]
The first panel of the day, chaired by Mary Clark, our co-founder and CEO, saw a group of Europe’s leading investors – Hakan Goker, M Ventures; Maina Bhaman, Sofinnova Partners; Christian Elling, Lundbeckfonden; and Roel Bulthuis, Syncona – share sage advice for companies looking to raise funds, providing insights on the most important factors shaping […]
Alentis Therapeutics is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and Claudin-1 (CLDN1) positive tumors Funding to advance clinical development of two first-in-class anti-CLDN1 antibodies and the platform to engineer CLDN1 antibody drug conjugates (ADC) and bi-specific antibodies Series C led by Jeito Capital together with Novo Holdings and RA Capital Management Naveed […]
Funding enables AMSilk to accelerate industrial scale-up and expand commercial operations of bio-fabricated silk protein materials Financing led by existing investors ATHOS (AT Newtec) with participation from Novo Holdings, Cargill, and MIG Capital. Munich, 4. April, 2023: AMSilk GmbH (“AMSilk”), the world’s first industrial supplier of bio-fabricated silk protein materials, today announced it has successfully raised […]
